Waters gets FDA clearance for OneFlow blood cancer tests
WAT•Waters received FDA 510(k) clearance for BD OneFlow LST and B-CLPD T1 tests to identify B-cell non-Hodgkin lymphoma. U.S. commercial availability is scheduled for spring 2027.
1. FDA clearance
Waters received FDA 510(k) clearance for BD OneFlow LST and B-CLPD T1 tests to identify B-cell non-Hodgkin lymphoma. U.S. commercial availability is scheduled for spring 2027.
